BiondVax signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center Göttingen, Germany
- Wednesday, December 22, 2021, 7:15
- Environment
- Add a comment
JERUSALEM, Dec. 22, 2021 /PRNewswire/ — BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced the…
About the Author
adminasapcorp has written 41672 stories on this site.